Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Roosevelt Daniel

Internal Medicine Bishopville, SC Medical Doctor

NPI 1275571846 CMS profile 102660

545 Sumter Hwy, Bishopville, SC 29010

Open in the dashboard

General payments

$5,141

192 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roosevelt Daniel of Bishopville, SC is reported in the CMS Open Payments database as having received $5,141 across 192 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,730 72
2024 General $1,858 77
2023 General $745 20
2022 General $539 12
2021 General $230 9
2020 General $39 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roosevelt Daniel
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Roosevelt Daniel were reported at $1,730. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Roosevelt Daniel Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $39 $119 $33–$402 $114
2021 $230 $135 $37–$521 $132
2022 $539 $141 $42–$496 $149
2023 $745 $149 $45–$519 $160
2024 $1,858 $154 $47–$537 $164
2025 $1,730 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $1,067 32 payments
  2. Novo Nordisk Inc $984 33 payments
  3. AstraZeneca Pharmaceuticals LP $882 33 payments
  4. Astellas Pharma US Inc $322 6 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $320 11 payments
  6. Lilly USA, LLC $257 14 payments
  7. ITI, Inc. $222 9 payments
  8. Amgen Inc. $190 9 payments
  9. Merck Sharp & Dohme Corporation $155 5 payments
  10. Pfizer Inc. $110 6 payments
  11. Other $632 34 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,845 187 payments
  2. Education $296 5 payments
Products named General payments · program years 2020–2025
  1. Ozempic $501 17 payments
  2. FARXIGA $489 16 payments
  3. VRAYLAR Neuroscience $428 12 payments
  4. AIRSUPRA $402 11 payments
  5. RYBELSUS $383 15 payments
  6. QULIPTA $347 10 payments
  7. Kerendia $320 11 payments
  8. UBRELVY $266 7 payments
  9. CAPLYTA $222 9 payments
  10. VRAYLAR Neuroscience $202 5 payments
  11. Other $2,429 132 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 158 drugs

Part D claims

8,747

Median for Internal Medicine: 777

Drug cost

$1,410,444

Median for Internal Medicine: $73,373

Branded share of claims

27.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 129 $194,600
Trulicity Dulaglutide Brand 77 $144,962
Jardiance Empagliflozin Brand 71 $127,150
Januvia Sitagliptin Phosphate Brand 90 $121,407
Mounjaro Tirzepatide Brand 67 $121,117
Eliquis Apixaban Brand 64 $98,755
Xarelto Rivaroxaban Brand 49 $70,980
Linzess Linaclotide Brand 53 $58,011
Farxiga Dapagliflozin Propanediol Brand 37 $57,640
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 40 $47,965

The 10 drugs with the highest cost, of 158 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$3,340

Medicare's payments for the services billed

Medicare patients

93

Average age 70

Services billed

294

59 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 49%
Chronic kidney disease 31%
Arthritis 28%
COPD 27%
Ischemic heart disease 26%
Atrial fibrillation 22%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $286
$286 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $227
$227 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $129
$129 37 —
MOUNJARO
  • Lilly USA, LLC $100
$100 67 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record